Table 1 Clinical characteristics and surgical outcomes
Patients who underwent postoperative prostate MRI (n = 73) | Patients in the whole series (n = 301) | |||
|---|---|---|---|---|
Age (years; mean ± SD; range) | 67.9 ± 5.4 | (53–76) | 68.7 ± 4.7 | (53–76) |
BMI (kg/m2; mean ± SD; range) | 24.1 ± 2.8 | (18.9–30.7) | 23.9 ± 2.8 | (16.8–33.4) |
Preoperative PSA level (ng/mL; mean ± SD; range) | 9.9 ± 6.9 | (4.0–43.4) | 9.5 ± 6.6 | (4.0–57.1) |
Clinical T stage (n, %) | ||||
 cT1 | 23 (30.3) | 148 (49.2) | ||
 pT2 | 49 (67.1) | 136 (45.2) | ||
 pT3 | 1 (1.4) | 17 (5.6) | ||
Biopsy Gleason’s score (n, %) | ||||
 ≦ 6 | 25 (34.2) | 94 (31.2) | ||
 = 7 | 30 (41.1) | 137 (45.5) | ||
 ≧ 8 | 18 (24.7) | 70 (23.3) | ||
Operative time (min; mean ± SD; range) | 182.3 ± 48.8 | (108–307) | 187.3 ± 44.4 | (103–313) |
Console time (min; mean ± SD; range) | 141.0 ± 41.7 | (76–250) | 145.6 ± 41.3 | (74–289) |
Estimated blood loss (mL; mean ± SD; range) | 98.1 ± 76.6 | (2–380) | 93.3 ± 99.4 | (1–650) |
Prostate volume (mL; mean ± SD; range) | 50.2 ± 24.2 | (10–175) | 44.1 ± 18.9 | (10–175) |
Pathological T stage (n, %) | ||||
 pT2 | 57 (78.1) | 226 (75.1) | ||
 pT3 | 16 (21.9) | 75 (24.9) | ||
Positive surgical margins (n, %) | ||||
 All stages | 11 (15.1) | 62 (20.1) | ||
 pT2 | 7 (12.3) | 29 (12.8) | ||
 pT3 | 4 (25.0) | 33 (44.0) | ||
Catheter removal period (days; mean ± SD; range) | 7.2 ± 0.8 | (6–13) | 7.5 ± 3 | (4–45) |
Postoperative hospital stay (days; mean ± SD; range) | 10.7 ± 2.2 | (8–20) | 10.9 ± 4.9 | (7–49) |
% continence (%) | ||||
 ≤ 1 month | 27.4 | 31.7 | ||
 ≤ 3 months | 53.4 | 51.2 | ||
 ≤ 6 months | 68.5 | 70.3 | ||
 ≤ 12 months | 84.9 | 78.8 | ||